"Project Lydia" for children with cancermadrid - Spagna
Each year are 1,400 children and adolescents with cancer are diagnosed in Spain, the 70% of them are leukemias, a type of blood cell cancer. Cancer is the leading cause of death in Spain among children between 5-14 years. It can´t be prevented and there are no measures for early diagnosis.
Totale finanziato €100%finanziato
Dreivip clienti 6.062€
Quelle persone che in maniera naturale hanno tratto beneficio dalle azioni portate avanti dal progetto
Quelle persone identificabili che ricevono un effetto potenziale dalle azioni portate avanti dal progetto.
- Materiali 1.562€
- Personale 4.500€
- Totale 6.062€
In a person with leukemia, some cells become abnormal and the body begins to produce them wildly and in large quantities. These abnormal cells infiltrate the bone marrow and affect the growth of normal progenitor cells invading the blood and other organs.
Project Lydia develops a clinical trial for children and adolescents with acute leukemia who do not respond to current treatments. Is adrressed to children with little healing options because they do not respond to chemotherapy or relapse after transplantation.
Cell therapy involves taking NK cells from patients or relatives (natural killer) are those that "kill" bad cells when they are recognized, but sometimes there is a malfunction of the immune system and these cells do not function.
In the laboratory they isolate the cells NK from the others they cultivate them multiplying them by million and they activate them, this way they are injected to the patient who receiving this army cells is able to reduce or even remove the cancer.
Chi ne trarrà beneficio?
1 children with cancer can be cure thanks to cell terapy.
Obiettivi del progetto
The patients in this trial are children who haven´t received a bone marrow transplant because the disease is widespread. The goal is to see if a cell therapy (NK cells) plus a special chemo would be able to recover them enough to have a marrow transplant and thus have a chance to heal.
CRIS Cancer è pienamente conforme ai 9 principi di trasparenza e buone pratiche analizzati dalla Lealtad Foundation